Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ARDX - Ardelyx, Inc. So'nggi Yangiliklar | Finranks

Home

/

ARDX

A

Ardelyx, Inc. (ARDX)

NGM – Real vaqt narxi. Valyuta: USD

6.61

0.00 (0.00%)

Yopilishda: May 12, 2026, 4:00 PM EDT

6.53

-0.08 (-1.21%)

Bozordan keyin: May 12, 2026, 7:45 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Ardelyx: Low Price, But High Implied Valuation

Ardelyx: Low Price, But High Implied Valuation

Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029. ARDX's ACCEL Phase III trial offers significant upside optionality, potentially tripling IBSRELA's addressable market if successful. DCF analysis yields a base-case share price of $24.27, well above current levels, even excluding ACCEL trial upside.

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans.

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers

Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know

Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should Know

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago.

Videolar

No Data

There is no data to display

Press-relizlar

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the presentation of a data analysis evaluating the long-term impact of XPHOZAH® (tenapanor) on serum electrolytes and selected nutrition biomarkers at the National Kidney Foundation's (NKF) Spring Clinical Meetings, currently underway in New Orleans.

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings

Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced an abstract, exploring the patient characteristics associated with irritable bowel syndrome with constipation (IBS-C) treatment patterns and their impact on gastrointestinal (GI) related healthcare resource utilization (HCRU), has been accepted as a poster presentation at the upcoming Digestive Disease Week Conference (DDW), to be held May 2-5, 2026, in Chicago.

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer

WALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W.